Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Ocrelizumab vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.58 [0.37, 0.91]
2 studies · 1651 participants
Low

Alemtuzumab 24 mg vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).

1 finding from 1 review

alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis 2017 · Cochrane Headline outcomes only
RR 0.34 [0.1, 1.16]
2 studies · 593 participants
Very low

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).

1 finding from 1 review

alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis 2017 · Cochrane Headline outcomes only
RR 0.33 [0.19, 0.56]
3 studies · 1414 participants
Low